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Background. Exercise 99mTc-tetrofosmin single-photon emission computed tomography
(SPECT) is a useful tool for short- and medium-term risk stratifications. Currently, the long-
term prognostic application of this technique has not been evaluated.
Methods and Results. Exercise 99mTc-tetrofosmin was performed in 655 consecutive
patients. Ten patients who underwent revascularization <60 days after nuclear testing were
excluded from the analysis. The present data are based on 638 patients with complete follow-up.
An abnormal SPECT study was defined as the presence of fixed and/or reversible perfusion
defects. End points were cardiac death, nonfatal infarction, and late coronary revasculariza-
tion. A total of 344 (54%) patients had an abnormal SPECT study. Perfusion defects included
fixed defects alone in 186 patients (29%) and reversible defects in 158 (25%) patients. During a
mean follow-up of 11.0 ± 3.3 years, 174 (27%) patients died (all-cause mortality). Nonfatal
myocardial infarction occurred in 76 (12%) patients, and late coronary revascularization was
performed in 194 (30%) patients. Univariable and multivariable Cox proportional hazard
regression analyses showed that exercise 99mTc-tetrofosmin SPECT provided prognostic
information incremental to clinical data and exercise test data. Patients with a normal SPECT
had a relatively favorable long-term prognosis, in contrast to patients with an abnormal study
who had a significantly increased risk of cardiac events. The SPECT parameters abnormal
scan, reversible defect, and summed rest score were strong predictors of long-term outcome.
Conclusion. Exercise 99mTc-tetrofosmin myocardial perfusion SPECT has an incremental
long-term prognostic value over clinical and stress test parameters for the prediction of major
adverse cardiac events. (J Nucl Cardiol 2012;19:907–13.)
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INTRODUCTION
Technetium-99m (99mTc)-labeled agents are cur-
rently the most frequently used radionuclide tracers for
the assessment of myocardial perfusion. Historically,
99mTc-labeled agents were developed to overcome some
limitations of thallium.1,2 These agents have a higher
photon energy and shorter physical half-life, resulting in
improved images quality and longer myocardial reten-
tion as compared to thallium.3 Multiple studies have
demonstrated the value of 99mTc-labeled tracers in
conjunction with single-photon emission computed
tomography (SPECT) for the diagnosis of coronary
artery disease, and the estimation of medium-term
prognosis.3-10 Several studies have demonstrated
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effective risk stratification with 99mTc-tetrofosmin myo-
cardial perfusion SPECT. Long-term outcome data after
exercise 99mTc-tetrofosmin myocardial perfusion SPECT
are currently not available. Therefore, the aim of this
study was to evaluate the long-term prognostic value of
exercise 99mTc-tetrofosmin SPECT for the prediction of
major adverse cardiac events in patients with known or
suspected coronary artery disease.
METHODS
Study Design
The study population consisted of 655 consecutive
patients, who underwent exercise 99mTc-tetrofosmin SPECT
imaging for the evaluation of known or suspected coronary
artery disease. The current report details the results of a repeat
follow-up from a prior study from our center.6 The reason to
perform this repeat follow-up study was to assess the very
long-term prognostic value of exercise 99mTc-tetrofosmin
myocardial perfusion SPECT. Diamond and Forrester clinical
score was used to stratify patients with suspected coronary
artery disease into groups with low, intermediate, or high
probability of coronary artery disease. All patients gave
informed consent before the test. The protocol was approved
by the Hospital Ethics Committee. Ten patients who under-
went revascularization \60 days after nuclear testing were
excluded from the analysis. This exclusion was based on the
previously published data indicating that referral to coronary
revascularization in the first 60 days after nuclear testing tends
to be based on the results of the scan and that referral to
revascularization [60 days after nuclear testing tends to be
based on the worsening of the patient’s clinical status.11 In
December 2010, follow-up was performed. The present data
are based on 638 patients with complete follow-up.
Clinical Data
A structured interview and clinical history were obtained,
and cardiac risk factors were assessed before nuclear testing. A
blood pressure C140/90 mm Hg, or treatment with antihyper-
tensive medication was considered as hypertension. A fasting
glucose level C7.8 mmol/L or the need for insulin or oral
hypoglycemic agents was considered as diabetes mellitus. A
total cholesterol C6.4 mmol/L, or treatment with lipid-lower-
ing medication was considered as hypercholesterolemia.
Exercise Testing
All patients fulfilled a symptom-limited upright bicycle
ergometry test with a stepwise increment of 20 W every
minute and with three electrocardiographic leads continuously
monitored. Cuff blood pressure measurements and twelve-lead
electrocardiograms were recorded at rest and every minute
during exercise and recovery. The Schiller system Cardiovit
CSG/12 (Schiller Inc., Baar, Switzerland) was used for
computer averaging of the electrocardiographic complexes.
Significant ST-segment depression was defined as a [1-mm
horizontal or downsloping ST-segment depression occurring at
80 ms after the J point.6 The target heart rate was defined as
85% of the maximum heart rate predicted for age and gender.
99mTc-Tetrofosmin SPECT Imaging
An intravenous dose of 370 MBq of 99mTc-tetrofosmin
(Myoview, Amersham, Buckinghamshire, United Kingdom)
was injected approximately 1 minute before the cessation of
exercise. In rest studies, 370 MBq of tetrofosmin was
administered at least 24 hours after the exercise study. Myo-
cardial images were acquired with a triple-head gamma-
camera system (Picker Prism 3000 XP, Cleveland, Ohio,
USA). For each study, six oblique (short axis) slices from the
apex to the base and three sagittal (vertical long axis) slices
were defined. Each of the six short-axis slices was divided into
eight equal segments. Owing to corresponding of the septal
part of the two basal slices to the fibrous portion of the
interventricular septum and normally exhibits reduced uptake,
this region was excluded from analysis. As a consequence, 47
segments were indentified (3 long axis and 44 short axis). The
interpretation of the scan was semiquantitatively performed by
visual analysis and aided by circumferential profiles analysis.
Exercise and rest tomographic views were reviewed side by
side by an experienced observer who was blind to the patients’
clinical information. A reversible perfusion defect was defined
as a perfusion defect on the exercise images that partially or
completely resolved at rest in C2 contiguous segments or
slices. A fixed perfusion defect was defined as a perfusion
defect on exercise images in two or more contiguous segments
or slices, which persists on rest images. The presence of a fixed
and/or reversible perfusion defect was considered as an
abnormal study. Each myocardial segment was assigned a
score from 0 to 3 (0 = normal; 1 = slightly reduced;
2 = moderately reduced; and 3 = severely reduced or absent
uptake). Summed stress score (SSS) and summed rest score
(SRS) were calculated by the summation of the scores of the
myocardial segments at stress and at rest, respectively. The
difference between stress and rest scores, summed difference
score (SDS), was considered representative of the extent and
severity of myocardial ischemia. Standard 17-segment-based
scores were calculated and converted into percent of the total
myocardium (% myocardium) by dividing the summed scores
by the maximum potential score, and multiplying by 100.12
Follow-Up
Collection of follow-up data was performed by contacting
the patient, the patient’s general practitioner, civil registries,
and review of hospital records. Outcome events were overall
mortality, cardiac death, nonfatal myocardial infarction, and
late ([60 days) coronary revascularization. A death caused by
acute myocardial infarction, significant arrhythmias, or refrac-
tory congestive heart failure was defined as cardiac death.
Sudden death occurring without another explanation was
included as cardiac death. Nonfatal myocardial infarction
was described by cardiac biomarker levels and ECG-changes.
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Major adverse cardiac events were the combined endpoint of
cardiac death, nonfatal myocardial infarction, or coronary
revascularization.
Statistical Analysis
Continuous variables were expressed as the mean ± SD
and analyzed using the Student’s t test. The chi-squared test
was used to compare categorical variables. Univariable and
multivariable Cox proportional hazard regression models were
performed to determine those variables which were indepen-
dent predictors of late cardiac events. Variables were selected
in a stepwise forward selection manner with entry and
retention set of a significance level of 0.05. The risk of a
variable was expressed as a hazard ratio (HR) with a
corresponding 95% confidence interval. The assumption of
the proportional hazards was evaluated by performing the log-
minus-log survival plot. The assumption was met. Interaction
terms were used to investigate collinearity; no interactions
were found. The incremental value of myocardial perfusion
SPECT over the clinical variables in the prediction of major
adverse cardiac events was evaluated using a multivariate
analysis including one pre-imaging model and three post-
imaging models. Survival curves were generated using the
Kaplan-Meier method to assess the probability of survival and
were compared using the log-rank test. P \ .05 was considered
statistically significant.
RESULTS
Clinical Characteristics and Exercise Test
Results
The characteristics of the 638 patients are presented
in Table 1. Diamond and Forrester pre-test probability of
coronary artery disease was low in 51 (8%), intermediate
in 364 (57%) and high in 223 (35%) patients. During the
exercise test, typical angina was observed in 106 patients,
and 124 patients showed significant ST-segment depres-
sion. Side effects were short ventricular tachycardia (\10
complexes) in, seven patients (1%), and atrial fibrillation
in 8 (1%) patients. Minor side effects included dizziness in
40 (6%) patients, headache in 18 (3%) patients, and
nausea in 12 (2%). Patients experienced no myocardial
infarction or ventricular fibrillation.
SPECT Results and Prognosis
A total of 344 (54%) patients had an abnormal
SPECT study. Perfusion defects included fixed defects
alone in 186 patients (29%) and reversible defects in 158
(25%) patients. Of these reversible defects, 56 were
completely reversible and 102 were partially reversible.
The means (SD) of the SPECT parameters SSS, SRS,
and SDS were 3.68 (2.86), 2.43 (2.55), and 1.25 (1.30),
respectively. During a mean follow-up of 11.0 ± 3.3
years, 174 (27%) patients died (all-cause mortality).
Nonfatal myocardial infarction occurred in 76 (12%)
patients, and late coronary revascularization was per-
formed in 194 (30%) patients. The Kaplan-Meier
survival curves are presented in Figures 1, 2, 3, 4, and
5. The survival curves show that a normal 99mTc-
tetrofosmin myocardial perfusion SPECT was associ-
ated with relatively low risk for major adverse cardiac
events. Conversely, patients with an abnormal study had
a significantly increased risk of major adverse cardiac
events. Figure 5 demonstrates survival curves for all-
cause mortality and nonfatal myocardial infarction
according to strata of coronary revascularization.
Table 1. Baseline characteristics
n 5 638
Number
(%)
Age (years) 56 ± 11
Women 210 (33)
Congestive heart failure 70 (11)
Diabetes mellitus 58 (9)
Hypercholesterolemia 268 (42)
Hypertension 275 (43)
Previous myocardial infarction 171 (27)
Previous coronary artery bypass graft 91 (11)
Previous percutaneous coronary
intervention
124 (19)
Known coronary artery disease 294 (46)
Smoking 153 (24)
Beta blockers 261 (41)
Calcium antagonists 269 (42)
A
Figure 1. Kaplan-Meier survival curves for major adverse
cardiac events (cardiac death, nonfatal infarction, and coronary
revascularization). Event-free survival was significantly dif-
ferent in patients with a normal and patients with abnormal
exercise 99mTc-tetrofosmin myocardial perfusion SPECT. y,
Years.
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Predictors of Outcome
Predictors of major adverse cardiac events are
demonstrated in Table 2. Univariable predictors of
major adverse cardiac events were age, male gender,
hypercholesterolemia, previous myocardial infarction,
revascularization, peak heart rate, rate-pressure product,
typical angina and all analyzed scan parameters. A
multivariable model revealed that myocardial perfusion
SPECT had an incremental prognostic value over
clinical variables and stress test parameters. The post-
imaging models demonstrated that an abnormal scan
was a powerful predictor of outcome; there was a direct
relation between an abnormal scan and the risk of major
adverse cardiac events.
DISCUSSION
The prognostic value of exercise 99mTc-tetrofosmin
myocardial perfusion SPECT has been reported in
previous studies with short-to-medium-term follow-
up.4-10 The long-term prognostic value of exercise
99mTc-tetrofosmin myocardial perfusion SPECT has
not been defined. This study demonstrates that the
prognostic value of exercise 99mTc-tetrofosmin myocar-
dial perfusion SPECT in predicting major adverse
cardiac events, all-cause mortality, and all-cause mor-
tality and nonfatal myocardial infarction was maintained
during a long-term follow-up of 11.0 ± 3.3 years. Uni-
variable and multivariable analyses showed that exercise
Figure 2. Kaplan-Meier survival curves for all-cause mortal-
ity. Event-free survival was significantly different in patients
with a normal and patients with abnormal exercise 99mTc-
tetrofosmin myocardial perfusion SPECT. y, Years.
A
Figure 3. Kaplan-Meier survival curves for all-cause mortal-
ity and nonfatal myocardial infarction. Event-free survival was
significantly different in patients with a normal and patients
with abnormal exercise 99mTc-tetrofosmin myocardial perfu-
sion SPECT. y, Years.
A
Figure 4. Kaplan-Meier survival curves for revascularization.
Event-free survival was significantly different in patients with
a normal and patients with abnormal exercise 99mTc-tetrofos-
min myocardial perfusion SPECT. y, Years.
Figure 5. Kaplan-Meier survival curves for the combined
endpoint of all-cause mortality or nonfatal myocardial infarc-
tion according to strata of coronary revascularization. Event-
free survival was not significantly different between patients
with and those without revascularization during follow-up. y,
Years.
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99mTc-tetrofosmin SPECT provided prognostic informa-
tion incremental to clinical data and exercise test data.
Patients with a normal SPECT had a relatively favorable
long-term prognosis, in contrast to patients with an
abnormal study who had a significantly increased risk of
cardiac events. The SPECT parameters abnormal scan,
reversible defect, and SRS were strong predictors of
long-term outcome.
Comparison to Previous Studies
Previous studies have demonstrated the prognostic
value of exercise 99mTc-tetrofosmin myocardial perfu-
sion SPECT for the prediction of cardiac events in
patients with known or suspected coronary artery disease
at short-medium term follow-up.4-10 Groutars et al4
studied 246 patients who had a normal exercise
thallium/99mTc-tetrofosmin myocardial perfusion
SPECT. The annualized cardiac event rate was 0.4%/
year during a 25 ± 3 month follow-up. Galassi et al5
studied 459 patients with exercise 99mTc-tetrofosmin
myocardial perfusion SPECT. During a median follow-
up of 38 months, the annualized event rate (cardiac death/
nonfatal infarction) was 0.5%/year in patients with a
normal study and 4.9%/year in those with an abnormal
study. Shaw et al7 reported the results from a multicenter
registry and described an excellent prognosis for patients
with a normal 99mTc-tetrofosmin myocardial perfusion
SPECT during a mean follow-up of 2.5 years
(30 months). Borges-Neto et al8 studied 473 patients
with 99mTc-tetrofosmin and 518 patients using 99mTc-
sestamibi exercise myocardial perfusion SPECT. The
study demonstrated that the type of 99mTc-labeled myo-
cardial perfusion agent did not affect interpretation of
Table 2. Predictors of major adverse cardiac events (cardiac death, nonfatal infarction, or revascu-
larization) at univariable and multivariable analyses
Univariable
analysis
Multivariable analysis
Pre-imaging
Post-imaging
I
Post-imaging
II
Post-imaging
III
Age* 1.02 (1.01–1.03) 1.05 (1.03–1.06) 1.03 (1.01–1.04) 1.02 (1.01–1.03) 1.05 (1.03–1.08)
Male gender 1.89 (1.50–2.39) 1.80 (1.29–2.51) P = .11 1.40 (1.09–1.79) 1.97 (1.25–3.10)
Congestive heart
failure
P = .69 P = .62 P = .65 P = .78 P = .15
Diabetes mellitus P = .22 1.96 (1.26–3.08) 1.74 (1.13–2.69) P = .13 2.36 (1.35–4.14)
History of angina P = .26 P = .63 P = .93 P = .66 P = .52
Hypercholesterolemia 1.30 (1.06–1.60) P = .79 P = .89 P = .17 P = .92
Hypertension P = .58 P = .82 P = .87 P = .10 P = .80
Previous infarction 1.58 (1.26–1.97) 1.71 (1.15–2.55) 1.51 (1.10–2.08) 1.33 (1.06–1.68) P = .06
Revascularization 4.54 (3.63–5.68) 1.93 (1.43–2.60) 3.23 (2.43–4.30) 3.64 (2.93–4.53) 3.11 (2.32–4.16)
Smoking P = .16 2.25 (1.50–3.38) 1.42 (1.03–1.94) P = .18 2.41 (1.60–3.64)
Exercise test results
Peak heart rate 0.87 (0.83–0.91) P = .16 P = .31 0.98 (0.97–0.99) P = .21
Peak systolic BP P = .91 P = .29 P = .16 P = .86 P = .11
Peak RPP 0.96 (0.95–0.98) P = .70 P = .94 P = .56 P = .93
Typical angina 1.68 (1.30–2.18) P = .40 P = .53 P = .94 P = .60
ST-segment changes P = .12 P = .10 P = .33 P = .20 P = .41
Scan parameters
Abnormal scan 1.68 (1.36–2.08) – 1.57 (1.12–2.20) – –
Reversible defect 1.94 (1.55–2.44) – – 1.62 (1.20–2.20) –
Fixed defect 1.28 (1.03–1.58) – – P = .47
SRS** 1.02 (1.01–1.02) – – – 1.03 (1.01–1.04)
SDS** 1.05 (1.04–1.07) – – – P = .49
SSS** 1.27 (1.15–1.46) – – – –
Statistically significant predictors of outcome are presented as hazard ratio (confidence interval), of all other variables the P value
is presented.
–, Not included in the model; BP, blood pressure; RPP, rate pressure product; SSS, summed stress score; SRS, summed rest score;
SDS, summed difference score.
* Per unit increment, ** per % myocardium increment.
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results for risk stratification and prognostic assessment
during the 1.5-year study period. Georgoulias et al9
studied 246 asymptomatic patients after percutaneous
coronary intervention with exercise 99mTc-tetrofosmin
gated-SPECT. During 8.3 ± 2.9-year follow-up of this
selected population, myocardial perfusion SPECT pro-
vided incremental prognostic value. However, routine
testing in asymptomatic patients is generally not recom-
mended, and the clinical value and cost-effectiveness of
routine SPECT after percutaneous coronary intervention
need further investigation. Recently, Jain et al10 studied
371 patients with exercise or pharmacologic stress 99mTc-
tetrofosmin gated-SPECT. During a mean follow-up of
3.9 years, SPECT findings significantly improved accu-
racy of cardiac event rate prediction compared to clinical
information alone.
Compared to these previous studies, our study
included 638 patients who were followed for 11.0 ±
3.3 years. The findings of the current study extend the
conclusions drawn from the previous medium-term
prognostic studies. Previously, we have reported the
4.0 ± 1.3-year follow-up of these 655 patients who
underwent exercise 99mTc-tetrofosmin myocardial perfu-
sion SPECT.6 In the same previous study, patients with a
normal study had an annualized event rate (cardiac death,
nonfatal infarction, and coronary revascularization) of
1.5%/year and those with an abnormal study of 5.0%/
year. In the current long-term follow-up study, Kaplan-
Meier survival curves continued to diverge over time.
Patients with normal SPECT had a favorable event-free
survival, indicating that the prognostic value of SPECT
for the prediction of outcome was maintained during the
long-term follow-up period. Hence, patients with normal
SPECT scans can be excluded from coronary invasive
procedures. In contrast, patients with an abnormal myo-
cardial perfusion SPECT had significantly higher
annualized event rates. A total of 294 (46%) patients
had known coronary artery disease; this may have caused
the relatively high event rate in this patient cohort.
Future studies are needed to optimize risk modifi-
cation to improve outcome in these patients.
The 10 excluded patients who underwent revascu-
larization \60 days after testing represent 1.6% of the
overall cohort. This percentage is relatively low because
in most of the patients with ischemia according
to exercise 99mTc-tetrofosmin, medical therapy was
probably optimized before a decision on referral to
percutaneous coronary revascularization or surgical
coronary revascularization was made. Kaplan-Meier
curves demonstrated that referral to coronary revascu-
larization was relatively low in patients with normal
scan results in the first 4 years after testing. Previous
studies demonstrate that the timing of revascularization
requires careful consideration.13 Patients with no or mild
symptoms and little ischemia can safely be treated with
medical treatment alone. Conversely, patients with
moderate-to-severe symptoms and/or extensive ischemia
should be strongly considered for revascularization
therapy.13 The current analysis demonstrates that
event-free survival from all-cause mortality and nonfatal
myocardial infarction was not significantly different
between patients with coronary revascularization during
follow-up and those without. This is in line with results
from the COURAGE trial which demonstrated that
clinical outcome was not significantly different between
patients with stable angina who received an initial
therapy of coronary revascularization and optimal med-
ical therapy compared with patients with optimal
medical therapy alone.14
Limitations
This study has several limitations. First, no atten-
uation or scatter correction was used during exercise
99mTc-tetrofosmin myocardial perfusion SPECT. Appli-
cation of attenuation or scatter correction may have
improved the accuracy of the SPECT studies. Recent
data indicate that attenuation correction may further
improve risk stratification.15,16 Second, previous studies
have demonstrated that functional data derived from
gated myocardial perfusion SPECT provides additional
information to predict outcome. At the time of data
collection, gated SPECT was not routinely performed.
Therefore, in this study, the prognostic value of gated
SPECT was not analyzed. Third, coronary angiography
was not routinely performed; therefore, the current
analysis may be influenced by false-positive and false-
negative SPECT studies. Fourth, although the feasibility
of the test was high, 72 (11%) patients had an incon-
clusive test (failure to achieve target heart rate and to
demonstrate a perfusion abnormality). These 72 studies
were considered normal. The feasibility and perhaps the
prognostic value could have been higher if beta-blocker
therapy was routinely discontinued before the exercise
test. Fifth, the results of exercise 99mTc-tetrofosmin
myocardial perfusion SPECT were available to the
treating physicians. Patient management decisions were
made at discretion of the treating physicians. It cannot
be excluded that patients with an abnormal study
received more intensive medical therapy and were
referred to coronary revascularization to favorably alter
their prognosis. Therefore the prognostic power of
exercise 99mTc-tetrofosmin myocardial perfusion
SPECT may have been underestimated in the present
study. Sixth, the present results were obtained in patients
who underwent exercise 99mTc-tetrofosmin imaging, and
cannot be automatically be extrapolated to SPECT
studies using other isotopes. Finally, clinical data upon
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which to adjust the multivariable model were relatively
limited; this could have influenced the current analysis.
CONCLUSION
Exercise 99mTc-tetrofosmin myocardial perfusion
SPECT has an incremental long-term prognostic value
over clinical and stress test parameters for the prediction
of major adverse cardiac events. Patients with a normal
99mTc-tetrofosmin SPECT have a relatively favorable
long-term prognosis, in contrast to patients with an
abnormal study who have a significantly increased risk
of cardiac events.
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